|
1.
|
|
15 p, 694.5 KB |
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms : results from the EPICOVIDEHA registry
/
Marchetti, Monia (Azienda Ospedaliera Nazionale) ;
Salmanton-García, Jon (University of Cologne, Cologne, Germany) ;
El-Ashwah, Shaimaa (Mansoura University. Oncology Center) ;
Verga, Luisa (Università Milano-Bicocca) ;
Itri, Federico (San Luigi Gonzaga Hospital-Orbassano, Orbassano, Italy) ;
Ráčil, Zdeněk (Institute of Hematology and Blood Transfusion, Prague, Czech Republic) ;
Dávila-Valls, Julio (Hospital Nuestra Señora de Sonsoles (Àvila)) ;
Martín-Pérez, Sonia (Hospital Nuestra Señora de Sonsoles (Àvila)) ;
Van Doesum, Jaap (University Medical Center Groningen, The Netherlands) ;
Passamonti, Francesco (University Insubria, Varese, Italy) ;
Abu-Zeinah, Ghaith (Division of Hematology and Oncology, Weill Cornell Medicine, New York) ;
Farina, Francesca (IRCCS Ospedale San Raffaele, Milan, Italy) ;
López-García, Alberto (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Dragonetti, Giulia (Fondazione Policlinico Universitario Agostino Gemelli-IRCCS, Rome) ;
Cattaneo, Chiara (Hematology Unit, ASST-Spedali Civili, Brescia, Italy) ;
Gomes Da Silva, Maria (Portuguese Institute of Oncology, Lisbon, Portugal) ;
Bilgin, Yavuz M. (Department of Internal Medicine, ADRZ, Goes, The Netherlands) ;
Žák, Pavel (University Hospital Hradec Kralove (República Txeca)) ;
Petzer, Verena (Medical University of Innsbruck, Austria) ;
Glenthøj, Andreas (Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark) ;
Espigado, Ildefonso (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Buquicchio, Caterina (Ospedale Dimiccoli Barletta, Italy) ;
Bonuomo, Valentina (University of Verona, Italy) ;
Prezioso, Lucia (Hospital University of Parma, Italy) ;
Meers, Stef (AZ KLINA, Brasschaat, Belgium) ;
Duarte, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Bergantim, Rui ;
Jakšić, Ozren ;
Čolović, Natasha ;
Blennow, Ola ;
Cernan, Martin ;
Schönlein, Martin ;
Samarkos, Michail ;
Mitra, Maria Enza ;
Magliano, Gabriele ;
Maertens, Johan ;
Ledoux, Marie-Pierre ;
Jiménez, Moraima (Hospital Universitari Vall d'Hebron) ;
Demirkan, Fatih ;
Collins, Graham ;
Cabirta, Alba (Hospital Universitari Vall d'Hebron) ;
Gräfe, Stefanie K. ;
Nordlander, Anna ;
Wolf, Dominik ;
Arellano, Elena ;
Cordoba, Raul ;
Hanakova, Michaela ;
Zambrotta, Giovanni ;
Nunes Rodrigues, Raquel ;
Limberti, Giulia ;
Marchesi, Francesco ;
Cornely, Oliver A. ;
Pagano, Livio ;
Universitat Autònoma de Barcelona
Patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPN) typically incur high rates of infections and both drugs and comorbidities may modulate infection risk. The present study aims to assess the effect of immunosuppressive agents on clinical outcomes of MPN patients affected by the coronavirus disease 2019 (COVID-19). [...]
2023 -  10.1177/20406207231154706
Therapeutic Advances in Hematology, Vol. 14 (march 2023)
|
|
|
2.
|
|
13 p, 1.6 MB |
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab : final analysis of the randomized, phase III iLLUMINATE trial
/
Moreno, Carol (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Greil, Richard (Salzburg Cancer Research Institute-CCCIT (Àustria)) ;
Demirkan, Fatih (Dokuz Eylul University (Turquía)) ;
Tedeschi, Alessandra (Niguarda Ca Granda Hospital (Itàlia)) ;
Anz, Bertrand (Tennessee Oncology (Estats Units)) ;
Larratt, Loree (University of Alberta Hospital (Canadà)) ;
Simkovic, Martin (University Hospital and Medical School Hradec (Txèquia)) ;
Novak, Jan (Charles University (Txèquia)) ;
Strugov, Vladimir (Almazov National Medical Research Centre (Rússia)) ;
Gill, Devinder (Princess Alexandra Hospital) ;
Gribben, John G. (Barts Cancer Institute) ;
Kwei, Kevin (Pharmacyclics LLC) ;
Dai, Sandra (Pharmacyclics LLC) ;
Hsu, Emily (Pharmacyclics LLC) ;
Dean, James P. (Pharmacyclics LLC) ;
Flinn, Ian W. (Sarah Cannon Research Institute) ;
Universitat Autònoma de Barcelona
iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. [...]
2022 - 10.3324/haematol.2021.279012
Haematologica, Vol. 107 (january 2022) , p. 2108-2120
|
|
|
3.
|
|
13 p, 1.9 MB |
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features : integrated analysis of two phase 3 studies
/
Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center) ;
Robak, Tadeusz (Medical University of Lodz. Copernicus Memorial Hospital) ;
Demirkan, Fatih (Dokuz Eylul University) ;
Bairey, Osnat (Rabin Medical Center) ;
Moreno, Carolina (Institut d'Investigació Biomèdica Sant Pau) ;
Simpson, D. (BeiGene) ;
Munir, Talha (Department of Haematology. St. James's Hospital) ;
Stevens, D.A. (Norton Cancer Institute) ;
Dai, S. (Pharmacyclics LLC. an AbbVie Company) ;
Cheung, Leo W. K (Pharmacyclics LLC. an AbbVie Company) ;
Kwei, Kevin (Pharmacyclics LLC. an AbbVie Company) ;
Lal, Indu (Pharmacyclics LLC. an AbbVie Company) ;
Hsu, E. (Pharmacyclics LLC. an AbbVie Company) ;
Kipps, Thomas J (University of California San Diego. Moores Cancer Center) ;
Tedeschi, A. (ASST Grande Ospedale Metropolitano Niguarda)
Genomic abnormalities, including del(17p)/TP53 mutation, del(11q), unmutated IGHV, and mutations in BIRC3, NOTCH1, SF3B1, and XPO1 predict poor outcomes with chemoimmunotherapy in chronic lymphocytic leukemia. [...]
2022 - 10.1080/10428194.2021.2020779
Leukemia and Lymphoma, Vol. 63 Núm. 6 (2022) , p. 1375-1386
|
|
|
4.
|
|
12 p, 770.4 KB |
COVID-19 in adult acute myeloid leukemia patients : a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
/
Marchesi, Francesco (IRCCS Regina Elena National Cancer Institute) ;
Salmanton-García, Jon (University of Cologne) ;
Emarah, Ziad (Mansoura University) ;
Piukovics, Klára (Medicine University of Szeged) ;
Nucci, Marcio (Federal University of Rio de Janeiro) ;
López-García, Alberto (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Rácil, Zdenék (Institute of Hematology and Blood Transfusion) ;
Farina, Francesca (IRCCS San Raffaele Scientific Institute (Milà, Itàlia)) ;
Popova, Marina (Pavlov University) ;
Zompi, Sofia (AOU Citta' della Salute e della Scienza) ;
Audisio, Ernesta (AOU Citta' della Salute e della Scienza) ;
Ledoux, Marie-Pierre (Institut de Cancérologie Strasbourg Europe) ;
Verga, Luisa (Università Milano-Bicocca) ;
Weinbergerová, Barbora (University Hospital Brno (República Txeca)) ;
Szotkovski, Tomas (University Hospital Olomouc (Olomouc, República Txeca)) ;
Da Silva, Maria Gomes (Portuguese Institute of Oncology) ;
Fracchiolla, Nicola (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico) ;
De Jonge, Nick (Amsterdam UMC) ;
Collins, Graham (Oxford University Hospitals) ;
Marchetti, Monia (Azienda Ospedaliera Nazionale "SS. Antonio e Biagio e Cesare Arrigo") ;
Magliano, Gabriele (ASST Grande Ospedale Metropolitano Niguarda) ;
Garcia-Vidal, Carolina (Universitat de Barcelona) ;
Biernat, Monika M. (Wroclaw Medical University) ;
Van Doesum, Jaap (University Medical Center Groningen) ;
Machado, Marina (Hospital General Universitario Gregorio Marañón) ;
Demirkan, Fatih (Dokuz Eylul University) ;
Al-Khabori, Murtadha (Sultan Qaboos University Hospital) ;
Žák, Pavel (University Hospital Hradec Kralove (República Txeca)) ;
Víšek, Benjamín (University Hospital Hradec Kralove (República Txeca)) ;
Stoma, Igor (Gomel State Medical University, Gomel) ;
Méndez, Gustavo-Adolfo (Hospital Escuela de Agudos Dr. Ramón Madariaga) ;
Maertens, Johan (KU Leuven) ;
Khanna, Nina (University Hospital Basel (Basilea, Suïssa)) ;
Espigado, Ildefonso (Universidad de Sevilla) ;
Dragonetti, Giulia (Fondazione Policlinico Universitario Agostino Gemelli) ;
Fianchi, Luana (Fondazione Policlinico Universitario Agostino Gemelli) ;
Del Principe, Maria Ilaria (Tor Vergata University of Rome) ;
Cabirta, Alba (Vall d'Hebron Institut d'Oncologia) ;
Ormazabal-Vélez, Irati (Complejo Hospitalario de Navarra) ;
Jakšić, Ozren (University Hospital Dubrava) ;
Buquicchio, Caterina (Ematologia con Trapianto (Itàlia)) ;
Bonuomo, Valentina (University of Verona) ;
Batinié, Josip (University Hospital Centre Zagreb) ;
Omrani, Ali S. (Hamad Medical Corporation) ;
Lamure, Sylvain (Universite de Montpellier) ;
Finizio, Olimpia (Università Cattolica del Sacro Cuore) ;
Fernández, Noemí (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Falces-Romero, Iker (Hospital Universitario La Paz (Madrid)) ;
Blennow, Ola (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Bergantim, Rui (Centro Hospitalar e Universitário São João (Portugal)) ;
Ali, Natasha (Aga Khan University Hospital) ;
Win, Sein (Yangon General Hospital) ;
Van Praet, Jens (AZ Sint-Jan Brugge-Oostende) ;
Tisi, Maria Chiara (Ospedale San Bortolo) ;
Shirinova, Ayten (Azerbaijan Scientific Research Hematology and Transfusiology Institute) ;
Schönlein, Martin (University Medical Center Hamburg-Eppendorf) ;
Prattes, Juergen (Medical University of Graz) ;
Piedimonte, Monica (AOU Sant'Andrea) ;
Petzer, Verena (Medical University of Innsbruck) ;
Navrátil, Milan (University Hospital of Ostrava) ;
Kulasekararaj, Austin (King's College Hospital NHS Foundation Trust) ;
Jindra, Pavel (University Hospital Pilsen) ;
Sramek, Jirí (University Hospital Pilsen) ;
Glenthøj, Andreas (Copenhagen University Hospital) ;
Fazzi, Rita (Azienda Ospedaliera Università Pisana) ;
De Ramón-Sánchez, Cristina (Instituto de Investigación Biomédica de Salamanca) ;
Cattaneo, Chiara (ASST-Spedali Civili) ;
Calbacho, Maria (Hospital Universitario 12 de Octubre (Madrid)) ;
Bahr, Nathan C. (University of Kansas Medical Center) ;
El-Ashwah, Shaimaa (Mansoura University) ;
Cordoba, Raul (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Hanakova, Michaela (Institute of Hematology and Blood Transfusion) ;
Zambrotta, Giovanni (Azienda Ospedaliera San Gerardo) ;
Zambrotta, Giovanni (Università Milano-Bicocca) ;
Sciumè, Mariarita (IRCCS Ca' Granda Ospedale Maggiore Policlinico) ;
Booth, Stephen (Oxford University Hospitals) ;
Rodrigues, Raquel Nunes (Portuguese Institute of Oncology) ;
Sacchi, Maria Vittoria (Azienda Ospedaliera Nazionale "SS. Antonio e Biagio e Cesare Arrigo") ;
García-Poutón, Nicole (Universitat de Barcelona) ;
Martín-González, Juan-Alberto (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Khostelidi, Sofya (North-Western State Medical University named after Iliá Ilich Méchnikov) ;
Gräfe, Stefanie (University of Cologne) ;
Rahimli, Laman (University of Cologne) ;
Ammatuna, Emanuele (University Medical Center Groningen) ;
Busca, Alessandro (AOU Citta' della Salute e della Scienza) ;
Corradini, Paolo (University of Milan) ;
Hoenigl, Martin (Medical University of Graz) ;
Klimko, Nikolai (North-Western State Medical University named after Iliá Ilich Méchnikov) ;
Koehler, Philipp (University of Cologne) ;
Pagliuca, Antonio (King's College Hospital NHS Foundation Trust) ;
Passamonti, Francesco (University of Insubria and ASST Sette Laghi) ;
Cornely, Oliver A. (University of Cologne) ;
Pagano, Livio (Università Cattolica del Sacro Cuore) ;
Universitat Autònoma de Barcelona
Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. [...]
2022 - 10.3324/haematol.2022.280847
Haematologica, Vol. 108 (may 2022) , p. 22-33
|
|
|
5.
|
|
10 p, 631.8 KB |
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL : analysis from the iLLUMINATE study
/
Greil, Richard (Salzburg Cancer Research Institute-CCCIT, Cancer Cluster Salzburg. IIIrd Medical Department Paracelsus Medical University) ;
Tedeschi, Alessandra (Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Anz, Bertrand (Tennessee Oncology. Department of Medical Oncology) ;
Larratt, Loree (University of Alberta Hospital. Department of Clinical Hematology) ;
Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ;
Gill, Devinder (Princess Alexandra Hospital. Department of Clinical Hematology) ;
Gribben, John G. (Queen Mary University of London, Barts Cancer Institute. Centre for Haemato-Oncology) ;
Flinn, Ian W. (Sarah Cannon Research Institute/Tennessee Oncology) ;
Wang, Zhengyuan (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ;
Cheung, Leo W. K. (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ;
Nguyen, Aaron N. (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ;
Zhou, Cathy (Pharmacyclics LLC, an AbbVie Company. Biostatistics) ;
Styles, Lori (Pharmacyclics LLC, an AbbVie Company. Clinical Science) ;
Demirkan, Fatih (Dokuz Eylül University. Department of Hematology) ;
Universitat Autònoma de Barcelona
The online version contains supplementary material available at 10. 1007/s00277-021-04536-6.
2021 - 10.1007/s00277-021-04536-6
Annals of Hematology, Vol. 100 (may 2021) , p. 1733-1742
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
